Further research, including in vivo studies, will help to comprehensively elucidate the precise molecular interplay between NLRP3 and FLT3, in order to strengthen the finding that combined inhibition of NLRP3 and FLT3 could represent a new therapeutic strategy for AML patients. This evidence concerns the gene NLRP3 and acute myeloid leukemia.